CoVac-1 vaccine shows promise for immunocompromised patients At the recent American Association for Cancer Research meeting in New Orleans, ScienceBoard.net spoke with the University of Tübingen’s Dr. Juliane Walz, professor of peptide-based immunotherapies, and research associate Claudia Tandler about the promising results their CoVac-1 vaccine has shown in immunocompromised patients.Read More
GVW and L7 discuss collaboration at Meeting on the Med At the Cell & Gene Meeting on the Med in Barcelona, Spain, ScienceBoard.net spoke with Louis Hendriks, managing director at Global Value Web (GVW), and Vasu Rangadass, president and CEO at L7 Informatics, about the collaboration between the companies.Read More
Forge Biologics shares plans for growth at Meeting on the Med Chief commercial officer John Maslowski and senior vice president of business development Magdalena Tyrpien of Forge Biologics spoke with ScienceBoard.net at the Cell & Gene Meeting on the Med in Barcelona, Spain, to discuss the return to live events and in-person collaboration, Forge's expansion, and how Forge's corporate culture and vision works for their growth.Read More
Mission Bio shares platform’s progress at Meeting on the Med Mission Bio CEO Yan Zhang, PhD, and associate director of business development (cell and gene therapies) Nori Ueno spoke with ScienceBoard.net at the Cell & Gene Meeting on the Med in Barcelona, Spain, about the company's recent accomplishments with Tapestri, Mission Bio's single-cell platform for DNA analysis.Read More
Market access and patient education take center stage at Meeting on the Med Companies and patient groups tackled reimbursement hurdles and access challenges in a discussion at the Cell & Gene Meeting on the Med last week in Barcelona, Spain. Titans of the pharmaceutical industry took the stage to discuss important issues facing the growing segment, including patient education, reimbursement, and clinical trials.Read More
COVID-19 protects unvaccinated from reinfection Unvaccinated people who have a previous COVID-19 infection have a level of protection from future infections that's comparable to protection provided by mRNA vaccines, according to a new study published on April 20 in JAMA Network Open.Read More
Cevec Pharmaceuticals CEO stresses challenges in producing AAV vectors It will be a real challenge to produce sufficient quantities of gene therapy products, in particular when it comes to adeno-associated virus (AAV) vectors, according to Nicole Faust, CEO and chief science officer of Cevec Pharmaceuticals. Faust talked to ScienceBoard.net at the Cell & Gene Meeting on the Med last week in Barcelona, Spain.Read More